

Fitgenes Limited

ASX: FIT | ACN 100 531 191

ASX Release

26 September 2014

The Company Announcements Office
ASX Ltd
via electronic lodgement

EXTENSION OF OFFER PERIOD

The Directors of Fitgenes Limited ("Company") provide the following update on the status of the Company and Fitgenes group entities.

Background

The shares in the Company are currently suspended from quotation pending a recapitalisation. In order to facilitate a capital raising, through the issue of new shares and re-compliance with Chapters 1 and 2 of the ASX Listing Rules, the Company lodged a replacement prospectus with ASIC on 1 August 2014 ("Prospectus").

Extension of offer period

The Directors have decided to extend the Closing Date under the Prospectus to **5pm AEST on 17 October 2014** (from 5pm AEST on 30 September 2014).

The Directors thank you for your ongoing support and patience while the Company and Fitgenes Australia prepare for the re-compliance process and we will continue to keep you informed as milestones are reached.

About Fitgenes

Fitgenes (ASX: FIT) is an Australian company, whose clinics deliver personalised, preventative healthcare using the Company's proprietary platform technology called Pracware™, which delivers one of the world's most advanced, evidence- and genomics-based healthcare and wellness programs.

Fitgenes has built a strong brand, commercially validated its services and products and established itself through a network of over 350 independent clinics across Australia, New Zealand, Singapore, Malaysia, Hong Kong and the USA. Its first Fitgenes branded clinic opened in Perth, Western Australia in June 2014.

For further particulars please contact:

Mark Rainbird
Director, Managing Director
BlueMount Capital
+61 7 3160 2840

Adam Blumenthal
Director, Corporate Finance
BBY Limited
+61 2 9226 0084